Patients with noncancer pain reported similar preference levels for naloxegol and polyethylene glycol 3350 for managing opioid-induced constipation, according to a study in The American Journal of Gastroenterology conducted by Darren Brenner, MD, of the Northwestern University Feinberg School of Medicine in Chicago and colleagues. The study of 246 patients at 53 sites found that 50.4% preferred naloxegol and 48% preferred PEG 3350. Read the study.
Patients show equal preference for PEG 3350, naloxegol to treat OIC
Sign up for ACG SmartBrief
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.